Sai Parenterals Ltd Sets November 1 Board Meeting for Q2 Results

Sai Parenterals Ltd has scheduled a board meeting for November 1, 2026, to consider unaudited financial results for the quarter and half year ended September 30, 2026. The disclosure is significant because it sets the date for the company’s Q2 FY27 and H1 FY27 financial update, following reported June-quarter revenue of ₹182.41 crore.

When will Sai Parenterals announce its Q2 FY27 results?

Sai Parenterals will hold its board meeting on Sunday, November 1, 2026, according to its October 27 intimation to BSE. The board is scheduled to consider and approve the unaudited financial results for the quarter and half year ended September 30, 2026.

The company’s announcement identifies the exercise as the declaration of unaudited quarterly and half-yearly results. The reported agenda also includes consideration of the standalone and consolidated results and the Limited Review Report for the relevant periods.

The meeting intimation was listed on October 27, 2026. It is a procedural corporate disclosure ahead of the results announcement and does not itself provide the September-quarter revenue, profit, margins, or earnings per share.

What financial period will Sai Parenterals review?

Sai Parenterals will review its performance for the three months and six months ended September 30, 2026. These periods correspond to the second quarter and first half of FY27, based on the company’s results schedule described in the announcement.

The results will provide the next reported financial update after the June 2026 quarter. The supplied financial information states that Sai Parenterals recorded revenue of ₹182.41 crore and profit of ₹7.92 crore in Q1 FY2026-27.

Separately, a historical metric series in the supplied data lists revenue at 33 for June 2025, 96 for December 2025, 198 for March 2026, and 179 for June 2026. As the unit for that series is not specified, those figures cannot be directly compared with the reported ₹182.41 crore June-quarter revenue.

Why is Sai Parenterals' trading window closed?

Sai Parenterals closed its trading window for designated persons and their immediate relatives from October 1, 2026, until 48 hours after declaration of the unaudited results. The company disclosed the closure on September 30 in connection with the September-quarter results process.

Such restrictions are intended to prevent trading by covered persons while they may possess unpublished price-sensitive information related to financial results. The closure remains linked to the timing of the eventual results declaration rather than simply the date of the board meeting.

The company also received a compliance certificate under SEBI Regulation 74(5) for the quarter ended September 30, 2026, according to an October 8 announcement. The supplied information says the certificate related to dematerialised securities compliance.

What other corporate changes has Sai Parenterals disclosed?

Sai Parenterals disclosed management and compliance-related changes in September 2026. The board approved the resignation of Ms. Shivali Aggarwal as Company Secretary and Compliance Officer, effective September 30, 2026.

The company subsequently appointed Mr. Ashwani Singh Bisht as Company Secretary and appointed Mr. Arvind as Chief Operating Officer, according to the board-meeting outcome referenced in the supplied disclosures. These changes preceded the scheduled November meeting for financial results.

The company also held its 25th Annual General Meeting on September 10, 2026, through video conference. The supplied information states that shareholders approved all 12 proposed resolutions with majority support, and the company filed the AGM outcome and scrutinizer’s report.

How will the results schedule affect investors and operations?

Sai Parenterals has scheduled an earnings conference call for November 2, 2026, at 2:00 PM IST, one day after the board meeting. The call is intended to allow investors and analysts to discuss operational and financial results for the quarter and half year ended September 30, 2026.

For shareholders, the key pending information is the actual September-quarter financial outcome, including revenue, profitability and any management commentary made available after approval. The board-meeting intimation does not require an immediate action from shareholders and does not establish a financial outlook.

The results will also enable the market to assess the company’s first-half performance against its June-quarter base. Until the unaudited statements are released, the available disclosed financial reference remains the Q1 FY27 revenue of ₹182.41 crore and profit of ₹7.92 crore.

Conclusion

Sai Parenterals has formally set November 1, 2026, as the date for its board to consider unaudited Q2 FY27 and H1 FY27 results for the period ended September 30. The announcement establishes the company’s reporting timetable, while the disclosed trading-window closure follows the results-related compliance process.

Investors will next watch for the board-approved financial statements and Limited Review Report, followed by the earnings conference call at 2:00 PM IST on November 2, 2026. Those disclosures are expected to provide the company’s reported September-quarter figures and management commentary.